Phase II evaluation of bisantrene in patients with renal cell carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use / Q000633:toxicity; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D001859:Bone Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene